The detection of N-nitrosamine impurities in medicines and the increasing presence of nitrosamine drug substance-related impurities (NDSRIs) have presented significant challenges for both drug manufacturers and regulatory agencies. The formation of NDSRIs has become a critical concern due to their potential to pose serious health risks to patients.
Understanding how to predict and manage the formation of NDSRIs is essential for ensuring high safety and quality standards during drug development and manufacturing. Given their potential carcinogenicity and occurrence in certain drug formulations, NDSRIs have prompted regulatory agencies such as the FDA, EMA, and WHO to issue stringent guidelines for their detection, mitigation, and prevention.
A thorough understanding of the mechanisms behind the formation of NDSRIs is crucial for developing and implementing effective control strategies to meet regulatory requirements and safeguard patient health
Understanding NDSRI Formation and Prediction Methods
Understanding the formation pathways of nitrosamine drug substance-related impurities (NDSRIs) and implementing predictive models along with analytical controls is essential for ensuring regulatory compliance and patient safety. The formation of NDSRIs can be influenced by various chemical and environmental factors during the drug development process.
By integrating computational screening tools, robust process controls, and advanced analytical methods, pharmaceutical companies can proactively identify and address nitrosamine risks. This comprehensive approach not only helps in predicting the formation of NDSRIs but also enables effective mitigation strategies to ensure high-quality and safe drug formulations throughout the manufacturing
NDSRIs typically form when secondary or tertiary amines present in a drug substance react with nitrosating agents such as sodium nitrite (NaNO₂) or nitrous acid (HNO₂). The primary pathways include:
NDSRIs form when secondary or tertiary amines in drug substances react with nitrosating agents (e.g., sodium nitrite, nitrous acid) under favorable conditions. The primary pathways include:
A. Direct Nitrosation
- Mechanism: Drug substances containing amine functional groups react with nitrosating agents, forming stable N-nitroso compounds.
- Conditions Favoring Nitrosation: Acidic pH (pH 3–5): Nitrite (NO₂⁻) protonates to form nitrous acid (HNO₂), an active nitrosating species, Presence of Oxidants: Oxidizing agents accelerate the conversion of amines into nitrosamines.
B. Degradation Pathways
- Drug Instability: Certain APIs degrade over time, forming amine-containing fragments that are susceptible to nitrosation.
- Examples: Proton pump inhibitors (PPIs) (e.g., ranitidine, nizatidine) degrade into nitrosatable amines. Beta-lactam antibiotics may hydrolyze, exposing amine groups.
C. Contamination During Manufacturing
- Sources of Nitrosating Agents:Raw materials (e.g., nitrite-contaminated excipients),Process water with residual nitrites,Cross-contamination from shared equipment.
D. Storage and Environmental Exposure
- Moisture & Humidity: Promotes hydrolysis of certain drugs, releasing nitrosatable precursors.
- Packaging Material Interactions: Leaching of nitrosating agents from container closure systems.
- High Temperatures: Accelerates nitrosation reactions over shelf life.
Accurately predicting the formation of Nitrosamine Drug Substance-Related Impurities (NDSRIs) is essential for ensuring pharmaceutical safety and compliance. Pharmaceutical companies rely on advanced computational models and analytical testing methods to proactively assess and mitigate the risks associated with NDSRI formation.
A. Computational Prediction Methods
Pharmaceutical manufacturers use in silico tools to predict the formation of NDSRIs based on chemical structures and potential reaction pathways:
- Structure-Activity Relationship (SAR) Models:
- Evaluate molecular structures to identify functional groups prone to nitrosation.
- Tools like Derek Nexus and OECD QSAR Toolbox assess the mutagenic potential of impurities linked to nitrosamine formation.
- Machine Learning & AI:
- Advanced predictive algorithms analyze large datasets to identify trends in NDSRI formation.
- Applications include assessing interactions between APIs and excipients and predicting degradation-related impurity formation.
B. Analytical Testing Methods
Advanced analytical methods provide precise detection and quantification of NDSRIs to confirm predictions and assess risks:
- Liquid Chromatography-Mass Spectrometry (LC-MS):
- High sensitivity for trace-level detection of NDSRIs.
- Commonly used in routine impurity profiling for APIs and finished drug products.
- Gas Chromatography-Mass Spectrometry (GC-MS):
- Effective for detecting volatile nitrosamines.
- Suitable for impurity analysis in solvent-extracted samples.
- High-Performance Liquid Chromatography (HPLC):
- Detects amine precursors that could lead to NDSRI formation.
- Supports stability studies by tracking impurity formation over time.
By integrating computational prediction models with robust analytical testing, pharmaceutical companies can proactively manage the risks of NDSRI formation, ensuring drug quality and patient safety.
Take the first step to implementation of nitrosamine guidelines with us
Contact us today to take the first step towards compliance and operational excellence in the pharmaceutical industry.
Set an appointmentRegulatory Frameworks for NDSRI Prediction
The formation of NDSRIs (Nitrosamine Drug Substance-Related Impurities) has become a significant concern in pharmaceutical manufacturing due to their potential carcinogenic risks. To address the risks associated with the formation of NDSRIs, global regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established structured risk assessment frameworks.
This document outlines the FDA and EMA’s stepwise approach to identifying, assessing, and controlling risks related to the formation of NDSRIs in pharmaceuticals. These guidelines are designed to help manufacturers proactively manage nitrosamine contamination and ensure compliance with evolving safety standards.
FDA and EMA Risk Assessment Framework
✅ Assess Active Pharmaceutical Ingredients (APIs):
- Determine if the API contains secondary or tertiary amines, which can serve as nitrosamine precursors.
- Evaluate the API’s stability under different storage conditions.
✅ Review Excipients & Solvents:
- Identify excipients that may contain amines or introduce reactive functional groups.
- Assess solvents used in the manufacturing process for potential contamination with nitrosating agents.
✅ Analyze Synthetic Route & Manufacturing Process:
- Identify intermediates, catalysts, and byproducts that may contribute to nitrosation risk.
- Evaluate synthetic steps where nitrites or nitrates might be introduced.
Key Consideration: APIs that degrade into amines or undergo structural modifications during formulation may present increased risks.
Once high-risk components are identified, the next step is to evaluate potential sources of nitrosating agents in the manufacturing environment.
✅ Screen for Nitrites & Nitrates:
- Analyze raw materials for the presence of nitrite or nitrate impurities.
- Test excipients, solvents, and water sources for possible nitrosating contaminants.
✅ Evaluate Manufacturing Equipment & Cross-Contamination Risks:
- Identify whether shared manufacturing equipment could introduce nitrites into production lines.
- Ensure cleaning validation procedures prevent cross-contamination.
✅ Control Water Sources & Processing Aids:
- Assess water quality, particularly for nitrite levels, as water is a potential source of nitrosating agents.
- Evaluate the impact of pH adjustments and chemical treatments on nitrosamine risk.
- Key Consideration: Even trace amounts of nitrosating agents can significantly contribute to nitrosamine formation in pharmaceutical products.
Environmental factors play a critical role in the rate and extent of nitrosation reactions. Regulatory guidelines emphasize controlling pH, temperature, and humidity to minimize nitrosamine formation risks.
✅ Monitor pH Conditions:
- Nitrosation reactions are acid-catalyzed, meaning they occur more readily in low-pH environments (pH < 5).
- Buffer formulations or pH adjustments should be carefully assessed.
✅ Control Temperature & Storage Conditions:
- Evaluate how temperature fluctuations impact the stability of amines and nitrosating agents.
- Implement controlled storage conditions to prevent degradation reactions.
✅ Assess Moisture & Humidity Effects:
- Increased moisture levels can accelerate nitrosation reactions.
- Proper packaging controls should be in place to reduce exposure to humidity.
Strategies for Managing and Controlling NDSRIs in Drug Development
Effective management of the formation of N-nitroso-Drug Substance-Related Impurities (NDSRIs) is essential for ensuring regulatory compliance and safeguarding patient safety. Addressing the formation of NDSRIs requires a structured approach that aligns with FDA, ICH M7, and USP guidance. The following stepwise strategy focuses on identifying, assessing, and mitigating the risks associated with NDSRI formation in pharmaceutical products.
✔ Structural Evaluation
- Identify secondary/tertiary amines in the drug substance that can form NDSRIs.
- Utilize in silico predictive tools (e.g., Lhasa Ltd.’s Derek Nexus) to assess mutagenic potential.
✔ Manufacturing & Process Evaluation
- Assess the synthetic route, starting materials, and intermediates for potential nitrosamine formation.
- Identify nitrosating agents from reagents, catalysts, solvents, and excipients.
- Evaluate potential cross-contamination risks in multi-product manufacturing facilities.
✔ Storage & Degradation Risk
- Study stability data to identify conditions leading to NDSRI formation.
- Consider packaging interactions, pH-dependent degradation, and temperature effects.
✔ Regulatory Risk Classification
- Apply ICH M7 (R1) framework to determine if an impurity is mutagenic and requires control.
- Assess potential NDSRI toxicity using FDA and EMA’s AI (Acceptable Intake) limits.
✔ Develop High-Sensitivity Methods
- Use LC-MS/MS, GC-MS, HRMS for accurate quantification of NDSRIs.
- Follow FDA, USP, and EP-recommended methods for nitrosamine analysis.
✔ Surrogate Testing & Standards
- Use validated surrogate methods when reference standards are unavailable.
- Compare with known nitrosamines (e.g., NDMA, NDEA) for risk extrapolation.
✔ Routine & Stability Testing
- Implement nitrosamine-specific testing at API release, formulation, and stability stages.
- Conduct forced degradation studies to simulate long-term impurity formation.
✔ Synthetic Route Modifications
- Modify API synthesis to eliminate nitrosating conditions (e.g., alternative solvents, catalysts).
- Optimize reaction pH, temperature, and sequence to reduce impurity formation.
✔ Excipient Selection & Formulation Adjustments
- Avoid excipients with high nitrate/nitrite content (e.g., certain preservatives).
- Incorporate antioxidants to inhibit nitrosamine formation in formulations.
✔ Manufacturing Process Optimization
- Implement robust cleaning validation to prevent carryover contamination.
- Establish in-process controls to detect and mitigate impurity formation early.
✔ Risk Assessment Reports
- Submit comprehensive risk assessments in NDAs, ANDAs, and DMFs per FDA guidance.
- Provide scientific justification for proposed impurity limits and analytical methods.
✔ Regulatory Engagement & Updates
- Align with FDA’s evolving nitrosamine control guidelines.
- Justify control strategies using toxicological data and AI calculations.
✔ Ongoing Monitoring & Lifecycle Management
- Establish a continuous monitoring program for NDSRIs in commercial products.
- Update risk assessments based on new regulatory insights and real-world data.
Conclusion
The proactive identification and control of the formation of NDSRIs are crucial to ensuring drug safety and maintaining regulatory compliance. By leveraging predictive modeling, advanced analytical techniques, and stringent manufacturing controls, pharmaceutical manufacturers can effectively mitigate the risks associated with the formation of NDSRIs, improve drug quality, and safeguard patient health. As research evolves, industry-wide collaboration and adherence to updated regulatory guidelines will remain vital in overcoming the challenges posed by nitrosamine impurities.
References
- https://www.fda.gov/drugs/spotlight-cder-science/determining-recommended-acceptable-intake-limits-n-nitrosamine-impurities-pharmaceuticals
- Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities
- Control of Nitrosamine Impurities in Human Drugs
- EMA Nitrosamine Guidance
- FDA Nitrosamine Guidance
- Control of nitrosamines in human drugs
- https://www.fda.gov/drugs/drug-safety-and-availability/information-about-nitrosamine-impurities-medications
- https://www.linkedin.com/pulse/what-nitrosamines-pharmaceutical-industry-alireza-zarei-r9lie/
- https://www.linkedin.com/pulse/role-big-data-nitrosamine-risk-assessment-sagar-pawar-qnkxe/
- https://zamann-pharma.com/2024/08/05/6-steps-to-reduce-nitrosamines-impurities-in-pharma-industry/
- https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/referral-procedures-human-medicines/nitrosamine-impurities
Sagar Pawar
Sagar Pawar, a Quality Specialist at Zamann Pharma Support, brings over 11 years of experience in Quality domain for the pharmaceutical and medical technology industries. Specializing in qualification, validation, Computer System Validation (CSV), and Nitrosamine activities, Sagar is currently focused on enhancing the Zamann Service portfolio by developing and implementing robust strategies to address Nitrosamine-related challenges. Outside of work, Sagar enjoys trekking and cooking. Connect with Sagar on LinkedIn to discuss topics related to equipment qualification, GMP Compliance and Nitrosamine-related challenges.
